Table of Contents
ISRN Hepatology
Volume 2013 (2013), Article ID 130384, 5 pages
http://dx.doi.org/10.1155/2013/130384
Research Article

Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy

1Section of Gastroenterology & Hepatology, Department of Internal Medicine, School of Medicine, Tulane University, 1430 Tulane Avenue, SL-35, New Orleans, LA 70112, USA
2Center for Liver Diseases, University of Miami, School of Medicine, 1500 NW 12th Avenue, Suite 1101, Miami, FL 33136, USA

Received 6 July 2013; Accepted 13 August 2013

Academic Editors: C. Domenicotti, Z.-Z. Lin, and D. Morioka

Copyright © 2013 Martin Moehlen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. T. Goldstein, F. Zhou, S. C. Hadler, B. P. Bell, E. E. Mast, and H. S. Margolis, “A mathematical model to estimate global hepatitis B disease burden and vaccination impact,” International Journal of Epidemiology, vol. 34, no. 6, pp. 1329–1339, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. Y.-F. Liaw and C.-M. Chu, “Hepatitis B virus infection,” The Lancet, vol. 373, no. 9663, pp. 582–592, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. E. B. Keeffe, D. T. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315–1341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. F. Lok and B. J. McMahon, “AASLD practice guideline update chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Lok, F. Zoulim, S. Locarnini et al., “Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management,” Hepatology, vol. 46, no. 1, pp. 254–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. Y.-F. Liaw, E. Gane, N. Leung et al., “2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B,” Gastroenterology, vol. 136, no. 2, pp. 486–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Matsuda, F. Suzuki, Y. Suzuki et al., “YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine,” Journal of Medical Virology, vol. 74, no. 2, pp. 361–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Matsuda, F. Suzuki, Y. Suzuki et al., “Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine,” Journal of Gastroenterology, vol. 39, no. 1, pp. 34–40, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Kobayashi, T. Ide, and M. Sata, “Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers,” Journal of Hepatology, vol. 34, no. 4, pp. 584–586, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Margeridon-Thermet, N. S. Shulman, A. Ahmed et al., “Ultra-deep pyrosequencing of hepatitis b virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients,” Journal of Infectious Diseases, vol. 199, no. 9, pp. 1275–1285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Amini-Bavil-Olyaee, S. Y. Hosseini, F. Sabahi, and S.-M. Alavian, “Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine,” International Journal of Infectious Diseases, vol. 12, no. 1, pp. 83–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Pollicino, G. Isgrò, R. Di Stefano et al., “Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients,” Antiviral Therapy, vol. 14, no. 5, pp. 649–654, 2009. View at Google Scholar · View at Scopus
  13. Y. Han, L. H. Huang, C. M. Liu et al., “Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients,” Journal of Gastroenterology and Hepatology, vol. 24, no. 8, pp. 1417–1423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Nguyen, R. T. Garcia, H. N. Trinh et al., “Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B,” Alimentary Pharmacology and Therapeutics, vol. 30, no. 11-12, pp. 1150–1158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. K. Fung, T. Mazzulli, M. El-Kashab et al., “Lamivudine-resistant mutation among treatment-naïve hepatitis B patients is common and may be associated with treatment failure,” Hepatology, vol. 48, supplement 1, p. 703A, 2008. View at Google Scholar
  16. B.-M. Liu, T. Li, J. Xu et al., “Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients,” Antiviral Research, vol. 85, no. 3, pp. 512–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Mirandola, D. Campagnolo, G. Bortoletto, L. Franceschini, M. Marcolongo, and A. Alberti, “Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B,” Journal of Viral Hepatitis, vol. 18, no. 7, pp. e212–e216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Fung, F. Wong, T. Mazzulli et al., “Pre-existing antiviral-resistant mutation may be associated with primary non-response to lamivudine among treatment-naïve chronic hepatitis B patients,” Hepatology, vol. 50, supplement 4, p. 523A, 2009. View at Google Scholar
  19. R. Salpini, V. Svicher, V. Cento et al., “Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs,” Antiviral Research, vol. 92, no. 2, pp. 382–385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Sayan, S. Ç. Akhan, and M. Meric, “Naturally occurring amino-acid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B,” Journal of Viral Hepatitis, vol. 17, no. 1, pp. 23–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Osiowy, K. A. Ng, J. Ho et al., “Prevalence of nucleoside/nucleotide analogue resistance among treatment-naïve endemically-exposed chronic hepatitis B individuals by ultra-deep pyrosequencing,” Hepatology, vol. 54, supplement 1, pp. 1067A–1068A, 2011. View at Google Scholar
  22. K. A. Ng, C. Osiowy, D. K. Wong et al., “Prevalence of lamivudine resistance mutations among treatment-naive endemically exposed chronic hepatitis B individuals is low and not linked to demographic predictors,” Hepatology, vol. 50, supplement 4, pp. 508A–509A, 2009. View at Google Scholar
  23. M. H. Nguyen, H. N. Trinh, R. T. Garcia et al., “No baseline mutations in the hepatitis B virus reverse transcriptase were detected in patients with treatment-naive chronic hepatitis B using INNO LIPA HBV DR 3: a prospective study,” Hepatology, vol. 50, supplement 4, p. 493A, 2009. View at Google Scholar
  24. M. H. Nguyen, H. N. Trinh, R. T. Garcia et al., “Hepatitis B virus (HBV) reverse transcriptase mutation is rare in treatment-naive patients with chronic hepatitis B, (CHB): a prospective multicenter study using INNO-LIPA HBV DR 3 assay,” Hepatology, vol. 54, supplement 1, p. 1080A, 2011. View at Google Scholar
  25. M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, and H. Mcdade, “Viral dynamics in hepatitis B virus infection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 9, pp. 4398–4402, 1996. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Osiowy, E. Giles, Y. Tanaka, M. Mizokami, and G. Y. Minuk, “Molecular evolution of hepatitis B virus over 25 years,” Journal of Virology, vol. 80, no. 21, pp. 10307–10314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Solmone, D. Vincenti, M. C. F. Prosperi, A. Bruselles, G. Ippolito, and M. R. Capobianchi, “Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen,” Journal of Virology, vol. 83, no. 4, pp. 1718–1726, 2009. View at Publisher · View at Google Scholar · View at Scopus